Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0800
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2637
    +0.0015 (+0.12%)
     
  • USD/JPY

    151.1800
    -0.1920 (-0.13%)
     
  • Bitcoin USD

    70,430.33
    -507.89 (-0.72%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Adverum's Data at ASGCT Further Supports Phase 2 Development Plans For Wet-AMD Gene Therapy

  • Adverum Biotechnologies Inc (NASDAQ: ADVM) has shared new data from the ADVM-022 development program in wet age-related macular degeneration (wet AMD).

  • The data were presented at the American Society of Gene and Cell Therapy (ASGCT) 2022 Annual Meeting.

  • It exhibited results of the non-human primate (NHP) studies that provide support for the new 6 X 10^10 vg/eye (6E10) dose that Adverum intends to include in its next clinical trial.

  • Related: Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD.

  • The human equivalent dose of 6E10 (3 X 10^10 vg/eye dose in NHP) demonstrated potential therapeutic levels in both aqueous humor and vitreous humor.

  • Administration of the human equivalent dose of 6E10 (3 X 10^10 vg/eye dose in NHP) was well tolerated. No adverse clinical signs were observed during the three-month study.

  • "These new data suggest the 6x10^10 vg/eye dose may provide therapeutic levels of aflibercept in the clinic and informs our dosing regimen in our upcoming Phase 2 trial," said Laurent Fischer, M.D., president and CEO at Adverum.

  • The company plans to initiate the Phase 2 study in wet AMD in Q3 2022, evaluating ADVM-022 at the 2x10^11 vg/eye dose and the new, lower 6x10^10 vg/eye dose with new enhanced prophylactic steroid regimens.

  • Price Action: ADVM shares closed 5.03% higher at $0.87 during after-hours trading on Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement